

April 1, 2014



Trevena Appoints Robert Prachar as Senior Vice President, Commercial and Corporate Strategy

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the appointment of Robert Prachar to the newly created position of Senior Vice President, Commercial and Corporate Strategy, effective immediately. Mr. Prachar, who has served as a full-time consultant for the Company since August 2013, brings over 20 years of commercial leadership experience in the life sciences industry.

"Bob has a strong track record of creating and executing effective commercial strategies, and we formally welcome him as a permanent member of our leadership team," stated Maxine Gowen, Ph.D., president and chief executive officer of Trevena. "Bob's expertise in corporate and brand strategy will be critical to driving our business forward, particularly as we advance our clinical candidates, including TRV130 and TRV734 for moderate to severe pain indications and TRV027 for acute heart failure, and deliver additional development candidates from our ABLE™ product platform."

"Trevena has already generated three novel, differentiated clinical candidates based on its proprietary product platform, each of which addresses a large market opportunity and offers a superior therapeutic profile compared to current GPCR treatments," stated Mr. Prachar. "I look forward to working with the Trevena team to maximize the potential of this high-value pipeline, and position the Company for continued growth over the long term."

Prior to joining Trevena, Mr. Prachar held the position of Senior Vice President, Enterprise Strategy and Portfolio Planning at Endo Health Solutions, Inc. Before that, he was Vice President and General Manager, Vyvanse®, at Shire plc, and prior to that, he was President, U.S. Operations for Neuropharm Inc., a development-stage pharmaceutical company. Mr. Prachar also worked at Centocor, Inc., a division of Johnson and Johnson, in various commercial leadership positions including Vice President, Rheumatology Franchise and Senior Director, New Business Development. Mr. Prachar received an M.B.A from the Wharton School of the University of Pennsylvania and a B.B.A. in Finance from James Madison University.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated biased ligand product candidates into the clinic - TRV027 to treat acute heart failure, TRV130 to treat moderate to severe acute pain intravenously, and

TRV734 to treat moderate to severe acute and chronic pain orally. Trevena also plans to advance additional product candidates in its portfolio, including a preclinical program focused on central nervous system indications.

Cautionary Note on Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, its future operations, clinical development of its therapeutic candidates, its plans for potential future product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the availability and timing of data from ongoing clinical trials, the uncertainties inherent in conducting clinical trials, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates and other factors discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission on March 20, 2014 and other filings the Company makes with the Securities and Exchange Commission from time to time. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Investor Contacts:

Trevena, Inc.
Roberto Cuca, 610-354-8840 x224
Senior vice president and chief financial officer
rcuca@trevenainc.com

or

Argot Partners
Andrea Rabney, 212-600-1902
President and chief executive officer
andrea@argotpartners.com

or

Media:

Argot Partners
Eliza Schleifstein, 917-763-8106
eliza@argotpartners.com

Source: Trevena, Inc.